Zealand Pharma President of US Operations on first launch: Timing was our most important goal

Zealand Pharma has started to launch its hypoglycemia treatment Zegalogue in the US. According to the president of the firm's US operations, this is a crucial time as Americans start returning to schools and the covid-19 pandemic has led the company to invest significantly in digital sales and promotion opportunites.

Zealand Pharma President of US Operations Frank Sanders | Photo: Zealand Pharma / PR

By launching low blood sugar treatment Zegalogue on the US market, Zealand Pharma is marking its transition from development company to commercial biotech company. Although it was established in 1998, the firm had never sent its own drug to market until last week.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs